It was another ugly week for shareholders in CSL Ltd (ASX: CSL).
While the share price finally steadied toward the end of the week, the damage had already been done.
CSL shares have crashed 19% over the past five trading days and are now down roughly 44% year to date and a staggering 59% over the past 12 months. For a company once considered one of the ASX's safest long-term growth machines, that is a brutal fall from grace.
So, what exactly is going on, and could a comeback finally be brewing?
Image source: Getty Images
Another downgrade sends investors running
The latest sell-off was sparked by yet another earnings downgrade.
CSL now expects FY26 revenue of US$15.2 billion on a constant currency basis and net profit after tax of around US$3.1 billion. That compares with FY25 revenue of US$15.6 billion and profit of US$3.3 billion.
Investors clearly were not impressed. The market has become increasingly impatient with CSL after several years of slowing growth, operational hiccups, and disappointing updates.
Once upon a time, investors treated CSL shares like royalty.
Now? The market seems to greet every announcement by nervously checking for hidden bad news. The company has battled weaker vaccine demand, restructuring headaches, leadership turnover, and ongoing operational challenges.
At the same time, healthcare stocks more broadly have fallen out of favour throughout 2026, making life even tougher for CSL shareholders.
Why confidence keeps fading
The biggest issue right now appears to be confidence.
For years, investors happily paid premium valuations on CSL shares because the ASX biotech company consistently delivered strong earnings growth and operational execution. That trust has taken a serious hit.
This latest downgrade only reinforced fears that earnings momentum remains under pressure. Management specifically pointed to weakness in China albumin pricing, inventory normalisation in the US immunoglobulin market, and several operational factors weighing on profitability.
Translation? Investors are tired of hearing about temporary problems that somehow keep sticking around. Right now, the market wants proof. Not promises.
That means CSL likely needs to deliver several periods of stabilising revenue growth and improving margins before sentiment meaningfully recovers.
Is the market becoming too pessimistic?
Despite all the negativity, writing off CSL completely may still be dangerous.
This remains Australia's largest biotechnology company with enormous global scale, powerful plasma collection operations, and leading healthcare products used worldwide.
Importantly, healthcare demand itself has not disappeared. If CSL can regain earnings momentum, investor sentiment could improve surprisingly quickly, especially after such a dramatic valuation reset.
Sometimes the market swings too far in both directions. And after a near-60% collapse over 12 months, some investors are beginning to wonder whether pessimism around CSL shares has become excessive.
What do brokers think?
Broker sentiment still leans cautiously optimistic overall.
Morgans recently retained its buy rating on CSL shares despite trimming its price target to $147.59. That still implies roughly 50% upside from current levels.
The broker acknowledged disappointment around the downgrade but noted the problems appear "primarily executional rather than structural".
Meanwhile, Bell Potter maintained its hold rating but sharply slashed its target price from $155 to $100. That new valuation sits only modestly above CSL's current share price of $97.96.
